HRP20080538T3 - Aryloxyethylamine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition - Google Patents

Aryloxyethylamine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition

Info

Publication number
HRP20080538T3
HRP20080538T3 HR20080538T HRP20080538T HRP20080538T3 HR P20080538 T3 HRP20080538 T3 HR P20080538T3 HR 20080538 T HR20080538 T HR 20080538T HR P20080538 T HRP20080538 T HR P20080538T HR P20080538 T3 HRP20080538 T3 HR P20080538T3
Authority
HR
Croatia
Prior art keywords
serotonin reuptake
combination
reuptake inhibition
receptor agonism
partial dopamine
Prior art date
Application number
HR20080538T
Other languages
English (en)
Croatian (hr)
Inventor
W. Feenstra Roelof
Stoit Axel
Terpstra Jan-Willem
L. Pras-Raves Maria
C. Mccreary Andrew
J. Van Vliet Bernard
B. Hesselink Mayke
G. Kruse Cornelis
J.M. Van Scharrenburg Gustaaf
Original Assignee
Solvay Pharmaceuticals B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals B.V. filed Critical Solvay Pharmaceuticals B.V.
Publication of HRP20080538T3 publication Critical patent/HRP20080538T3/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
HR20080538T 2004-12-08 2008-10-22 Aryloxyethylamine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition HRP20080538T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63407404P 2004-12-08 2004-12-08
EP04106394 2004-12-08
PCT/EP2005/056505 WO2006061376A1 (en) 2004-12-08 2005-12-06 Aryloxyethylamine derivatives with a combination of partial d0pamine-d2 receptor agonism and serotonin reuptake inhibition

Publications (1)

Publication Number Publication Date
HRP20080538T3 true HRP20080538T3 (en) 2008-12-31

Family

ID=35744728

Family Applications (2)

Application Number Title Priority Date Filing Date
HR20080538T HRP20080538T3 (en) 2004-12-08 2008-10-22 Aryloxyethylamine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition
HR20090015T HRP20090015T3 (en) 2004-12-08 2009-01-13 Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition

Family Applications After (1)

Application Number Title Priority Date Filing Date
HR20090015T HRP20090015T3 (en) 2004-12-08 2009-01-13 Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition

Country Status (18)

Country Link
EP (4) EP1824480A1 (xx)
JP (4) JP2008523030A (xx)
KR (4) KR20070085959A (xx)
AT (2) ATE413173T1 (xx)
AU (4) AU2005313311A1 (xx)
BR (1) BRPI0518613A2 (xx)
CA (4) CA2587202A1 (xx)
DE (2) DE602005008471D1 (xx)
DK (2) DK1827427T3 (xx)
ES (2) ES2311245T3 (xx)
HR (2) HRP20080538T3 (xx)
IL (4) IL183063A0 (xx)
NO (4) NO20072969L (xx)
PL (2) PL1827427T3 (xx)
PT (2) PT1824479E (xx)
RU (4) RU2007125659A (xx)
SI (2) SI1824479T1 (xx)
WO (4) WO2006061378A1 (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007085651A1 (en) * 2006-01-30 2007-08-02 Speedel Experimenta Ag Process for the stereoselective preparation of alcohols from alpha, beta- insaturated compounds
US8063062B2 (en) 2006-12-20 2011-11-22 Solvay Pharmaceuticals B.V. Compounds with a combination of cannabinoid-CB1 antagonism and acetylcholinesterase inhibition
US8138174B2 (en) 2007-01-10 2012-03-20 Solvay Pharmaceuticals B.V. Compounds with a combination of cannabinoid CB1 antagonism and serotonin reuptake inhibition
CA2671554A1 (en) * 2007-01-10 2008-07-17 Solvay Pharmaceuticals B.V. Compounds with a combination of cannabinoid-cb1 antagonism and serotonin reuptake inhibition
RU2480462C2 (ru) * 2007-04-23 2013-04-27 Янссен Фармацевтика Н.В. Производные пиридина, используемые в качестве быстро диссоциирующихся антагонистов допаминовых рецепторов 2
PT2148873E (pt) * 2007-04-23 2012-11-20 Janssen Pharmaceutica Nv Derivados da 4-alcoxipiridazina antagonistas de dissociação rápida do recetor da dopamina 2
MX2009011416A (es) * 2007-04-23 2009-11-05 Janssen Pharmaceutica Nv Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida.
CN103360342B (zh) * 2012-04-09 2015-12-16 江苏恩华药业股份有限公司 3-氰基苯胺烷基芳基哌嗪衍生物及在制备药物中的应用
CN103570698B (zh) * 2012-08-01 2016-08-03 江苏恩华药业股份有限公司 用于制备维拉佐酮的化合物及其中间体和应用
ITMI20130392A1 (it) * 2013-03-15 2014-09-16 Dipharma Francis Srl Sintesi di un inibitore della ricaptazione della serotonina
EP3010586A1 (en) 2013-06-21 2016-04-27 Lupin Limited Substituted heterocyclic compounds as crac modulators
US9790231B2 (en) 2013-06-24 2017-10-17 Lupin Limited Chromane and chromene derivatives and their use as CRAC modulators
CN104337812B (zh) 2013-07-29 2018-09-14 广东东阳光药业有限公司 取代的杂芳基化合物及其使用方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692264B1 (fr) * 1992-06-12 1994-08-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
EP0900792B1 (en) * 1997-09-02 2003-10-29 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists
AU3386199A (en) * 1998-04-08 1999-10-25 American Home Products Corporation N-aryloxyethyl-indoly-alkylamines for the treatment of depression (5-ht1a receptor active agents)
AU765317C (en) * 1998-06-19 2004-05-20 H. Lundbeck A/S 4,5,6 and 7-indole and indoline derivatives, their preparation and use
AR022303A1 (es) * 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
BR0013498A (pt) * 1999-08-23 2002-05-14 Solvay Pharm Bv Composto, método para a preparação do mesmo, composição farmacêutica, e, métodos para a preparação da mesma e para o tratamento de distúrbios do snc
KR20050085472A (ko) * 2002-12-10 2005-08-29 메르크 파텐트 게엠베하 인돌 유도체 및 ５-ｈｔ 리간드로서의 이의 용도

Also Published As

Publication number Publication date
PT1824479E (pt) 2009-01-30
CA2587381A1 (en) 2006-06-15
DE602005008471D1 (de) 2008-09-04
HRP20090015T3 (en) 2009-02-28
ATE413173T1 (de) 2008-11-15
JP2008537725A (ja) 2008-09-25
JP2008523031A (ja) 2008-07-03
IL183061A0 (en) 2007-09-20
WO2006061376A1 (en) 2006-06-15
SI1824479T1 (sl) 2009-04-30
KR20070085959A (ko) 2007-08-27
AU2005313312A1 (en) 2006-06-15
SI1827427T1 (sl) 2008-12-31
EP1824480A1 (en) 2007-08-29
RU2007125660A (ru) 2009-01-20
IL183063A0 (en) 2007-09-20
IL183064A0 (en) 2007-09-20
EP1824479A1 (en) 2007-08-29
PL1824479T3 (pl) 2009-04-30
PT1827427E (pt) 2008-11-03
DK1824479T3 (da) 2009-03-09
CA2587202A1 (en) 2006-06-15
AU2005313311A1 (en) 2006-06-15
EP1824479B1 (en) 2008-11-05
CA2587357A1 (en) 2006-06-15
AU2005313390A1 (en) 2006-06-15
KR20070085916A (ko) 2007-08-27
EP1827427A1 (en) 2007-09-05
AU2005313391A1 (en) 2006-06-15
IL183062A0 (en) 2007-09-20
WO2006061379A1 (en) 2006-06-15
EP1827426A1 (en) 2007-09-05
DE602005010902D1 (de) 2008-12-18
DK1827427T3 (da) 2008-11-24
KR20070085975A (ko) 2007-08-27
WO2006061378A1 (en) 2006-06-15
CA2587559A1 (en) 2006-06-15
ES2317335T3 (es) 2009-04-16
NO20072974L (no) 2007-08-23
RU2007125659A (ru) 2009-01-20
ES2311245T3 (es) 2009-02-01
JP2008523029A (ja) 2008-07-03
JP2008523030A (ja) 2008-07-03
PL1827427T3 (pl) 2009-01-30
NO20072981L (no) 2007-09-05
BRPI0518613A2 (pt) 2008-11-25
WO2006061377A1 (en) 2006-06-15
NO20072969L (no) 2007-08-31
EP1827427B1 (en) 2008-07-23
NO20072977L (no) 2007-09-05
KR20070085988A (ko) 2007-08-27
RU2007125661A (ru) 2009-01-20
RU2007125658A (ru) 2009-01-20
ATE401883T1 (de) 2008-08-15

Similar Documents

Publication Publication Date Title
IL183064A0 (en) Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition
SG151254A1 (en) Substituted morpholine and thiomorpholine derivatives
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
IL176111A0 (en) 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri
MX2009003713A (es) Inhibidor de progresion de enfermedad de alzheimer que contiene un compuesto heterociclico con estructura especifica.
TW200745122A (en) New compounds I
TW200716564A (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
TW200621703A (en) Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
TW200631952A (en) Benzdioxan piperazine derivatives with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
TW200633987A (en) Phenylpiperazines with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
TW200740766A (en) Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6-ligands
TW200640898A (en) Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission
TW200716555A (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
TW200634009A (en) Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition
WO2007004041A3 (en) New compounds and their pharmaceutical use
NO20073390L (no) Fenylpiperaziner med en kombinasjon av affinitet for dopamin-D2-reseptorer og serotoningjenopptaksseter
CY1106649T1 (el) Νεα 1-μεθοξυ-2-φαινυλ-αιθενια χρησιμα δια την παρασκευην 5-καρβοξαλδεϋδο-2,3-διϋδροβενζοξεπινων
TW200716565A (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents